Back to the news

OncoDNA announces the reimbursement of its OncoSTRAT&GO Precision Medicine solution in the UK by major health insurers

BUPA Global Insurance has a specific code (7331B) for the reimbursement of OncoSTRAT&GO

Gosselies, Belgium – September 17th 2017 

OncoDNA SA announces today that major health insurers, including BUPA Global Insurance, have approved reimbursement in the United Kingdom for its OncoSTRAT&GO test, to find the most appropriate treatment options for each appropriate cancer patient.

OncoSTRAT&GO is a Precision Medicine solution that combines the analysis of a solid biopsy sample (of the primary tumour or of a metastasis) and the analysis of a liquid biopsy (from a blood sample). This integrated approach, combining DNA and protein profiling of the cancer sample with heterogeneity detection in the circulating tumour DNA (ctDNA), provides a complete genetic profile of the tumour which can be used to predict response to novel and promising new therapies like immunotherapies or targeted therapies but also to classical chemotherapies.

BUPA Global Insurance has a specific code (7331B) for the reimbursement of OncoSTRAT&GO. A direct contract is in place between the two companies.

For all other major UK insurance companies, there is a generic code, BC001211.  Oncologists can reference this code to any insurer when requesting the test and when the insurer authorises it for a patient, it can then be reimbursed.

« With this great news, many more cancer patients in the UK will be able to benefit from precision medicine and thus be better armed to fight the disease » Jean-Pol Detiffe, CEO of OncoDNA

« This is another major step forward for OncoDNA and its products. Its with great pleasure that EGL have been allowed to work with OncoDNA and the leading UK insurers in this exciting field. As a partnership we focus on education and reinforcing the benefits to patients and their oncologists together. The quality of the solution giving value for money and offering an ethical next step for patients in need of a clearer choice in their clinical pathway. Oncologists in need of a solution for their patients, should now have easier access to this test and hopefully will be requesting more regularly with confidence of gaining approval. » James Price, CEO of Everything Genetic Ltd

More information about OncoSTRAT&GO solution: 

https://www.oncodna.com/en/solution/oncostratgo

About Everything Genetic Ltd. 

Everything Genetic Ltd enables diagnostic, prognostic and theranostic-focused companies to rapidly assess and gain access to the UK IVD markets. We cover breast, ovarian, colorectal and urological cancers. We offer simple business consultancy-based support or deeper level distributor sales support or a combination of the two. Everything Genetic Ltd offers a solution to many of the issues facing patients and health professionals alike.

More information at https://everythinggeneticltd.co.uk